Genmab A (GMAB) Common Equity (2018 - 2026)

Genmab A (GMAB) has reported Common Equity for 9 consecutive years, with $6.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 12.35% year-over-year to $6.0 billion; the trailing twelve-month figure through Jun 2026 stood at $6.0 billion (up 12.35% YoY), and the FY2025 full-year result was $5.8 billion, up 13.82% from the prior year.
• Common Equity improved to $6.0 billion in Q2 2026 per GMAB's latest filing, from $5.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $6.0 billion in Q2 2026 and bottomed at $10.0 million in Q3 2024.
• Historically, Common Equity has averaged $3.1 billion across 5 years, with a median of $2.9 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Common Equity slumped 99.68% in 2025, then jumped 56720.0% in 2026.
• Over 5 years, Common Equity stood at $2.6 billion in 2022, then climbed by 13.18% to $3.0 billion in 2023, then gained by 14.98% to $3.4 billion in 2024, then surged by 71.25% to $5.8 billion in 2025, then advanced by 1.88% to $6.0 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $6.0 billion, $5.7 billion, and $5.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.